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To make sure that novel human cell-based products contribute to human health care, it is essential that,
based on sound science at present, suitable measures be taken by the manufacturers and regulatory
authorities on applying these products to the treatment of patients by taking into account speciﬁcity of
starting cell lines, the manufacturing process, products, administration procedures, diseases in question,
and patient population. As part of such an endeavor, we studied scientiﬁc principles, concepts, and basic
technical elements to ensure the quality and safety of therapeutic products derived from autologous
human somatic stem cells, taking into consideration scientiﬁc and technological advances, ethics, reg-
ulatory rationale, and international trends in human stem cell-derived products. This led to the devel-
opment of the Japanese ofﬁcial Notiﬁcation No. 0907-2, “Guideline on Ensuring the Quality and Safety of
Pharmaceuticals and Medical Devices Derived from the Processing of Autologous Human Somatic Stem
Cells,” issued by Pharmaceuticals and Food Safety Bureau, Ministry of Health, Labour and Welfare of
Japan on September 7, 2012. The present paper describes the background information and the devel-
opment of our study and the resulting guidance. For products derived from autologous somatic stem
cells, major points to consider include 1) multipotency and self-replication ability of autologous human
somatic stem cells and differences in cell characteristics of the ﬁnal products from those of the starting
cells; 2) a donor's infectious status; 3) the risk of proliferation/reactivation of viruses during the
manufacturing processes; 4) robust process control to minimize unevenness of “custom-made” products;
5) a limited amount of samples for quality evaluation of products; and 6) robust application and function
of the ﬁnal products in a cell environment different from where the original cells were localized and
were performing their natural endogenous functions. The ultimate goal of this guidance is to provide
suitable medical opportunities as soon as possible to the patients.
© 2015, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).s a distinct product from both conventional pharmaceuticals and medical devices according to the revised Pharma-
nd Medical Devices, and Other Therapeutic Products Act. (Akinori Hara, Daisaku Sato, and Yasuyuki Sahara: New
Therapies in Japan. Therapeutic Innovation & Regulatory Science. 2014; 48(6): 681e688.)
.jp, hayakawatakao@gmail.com (T. Hayakawa).
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clinical research will lead to the smooth development of relevantDevelopment of regenerative medicine using cell-based prod-
ucts that are derived from the processing of human cells and tissues
is keenly anticipated in Japan because of difﬁculties in securing
human organs and tissues in our country. With technology break-
throughs and research advances, people are increasingly hopeful
that medical technology involving novel cell-based products will
develop into new therapies.
At a meeting of the Japanese Council for Science and Technology
Policy held in November 2007, opinions were exchanged regarding
induced pluripotent stem (iPS) cells, which were attracting
considerable attention. The need to encourage and accelerate
research on regenerative medicine was voiced. Subsequently, there
was a rapid movement towards the realization of new cellular
therapies. Thus, action to ensure the smooth and efﬁcient evalua-
tion of products expected in the near future has become necessary.
The utilization of human stem cells, particularly human em-
bryonic stem (ES) cells, in regenerativemedicine had been regarded
as difﬁcult and has been limited by ethical considerations. How-
ever, in the United States, concrete efforts were recently made to
test human stem cells in clinical trials. Research into the use of
mesenchymal stem cells and induced pluripotent stem (iPS) cells is
now conducted around the world. Identifying (at an early stage of
development) the technical, medical, and ethical conditions
necessary for the utilization of various types of stem cells is vital for
their rapid application in patients.
In Japan, there have been 2 main approaches to the research,
development, and clinical application of cell-based regenerative
medicine. The ﬁrst one is aimed at the marketing authorization of
cell- and tissue-based products under the Japanese Pharmaceutical
Affairs Law. In other words, this ﬁrst approach involves research
and development initiated by a company and follows a stepwise
process toward evaluation and approval of the product by the
relevant regulatory authorities. These steps include 1) regulatory
consultation with respect to the quality and safety of a product to
ensure that there are no obstacles to its application to human
health care in clinical trials, 2) clinical trials, 3) product marketing
authorization (manufacturing and import approval), and ﬁnally 4)
clinical use. When adopting this kind of approach, applicants are
encouraged to refer to certain ofﬁcial guidelines, such as Pharma-
ceutical Notiﬁcation No. 1314 entitled “Ensuring the Quality and
Safety of Pharmaceuticals andMedical DevicesManufactured Using
Ingredients Derived from Humans and/or Animals,” dated
December 26, 2000. The second approach is “human stem cell
clinical research” conducted, for the time being, according to the
Medical Act. This is carried out in accordance with Japanese Min-
istry of Health, Labour andWelfare Notiﬁcation No. 0703003, dated
July 3, 2006, and entitled “Guideline Concerning Clinical Research
Using Human Stem Cells,” though the scientiﬁc contents are, on the
whole, based on the aforementioned Pharmaceutical Notiﬁcation
No. 1314. Revised versions of Notiﬁcation No. 0703003 were pub-
lished in November 2010 and October 2013, although the chemis-
try, manufacturing, and control (CMC) parts therein are based on
Japanese Ministry of Health, Labour and Welfare Notiﬁcations No.
0208003 and No. 0912006, described later. Whether “human stem
cell clinical research” can proceed will depend on deliberations at
the Japanese Ministry of Health, Labour and Welfare Scientiﬁc
Committee Meeting (most reviews are conducted by competent
expert committees) and the decision of the Minister of Health,
Labour andWelfare. As human stem cell clinical research proceeds,
research will be eligible to receive public funding as a “high level/
advanced therapy” if it is determined, from the standpoint of efﬁ-
cacy and safety, to be medical treatment within the publicproducts by the industry.
The 2006/2007 scientiﬁc research group (group leader, Dr.
Takao Hayakawa) of the Japanese Ministry of Health, Labour and
Welfare inquired into preparing a revised version of “Guideline
on Ensuring the Quality and Safety of Pharmaceuticals and
Medical Devices Derived from the Processing of Human Cells and
Tissues,” which is Appendix 2 in Pharmaceutical Notiﬁcation No.
1314, mentioned above, in response to requests that Japan should
move forward with appropriate regulations for cell-based
regenerative medicine by updating standards to reﬂect rapidly
developing science and technology, ethical viewpoints, and in-
ternational trends. The revised version was originally drafted as a
single guideline. However, it was later split into 2 guidelines in
order to clarify the speciﬁc technical requirements for products
derived from autologous cells and allogeneic cells. The
autologous-cell guideline, entitled “Guideline on Ensuring the
Quality and Safety of Products Derived from the Processing of
Autologous Human Cells/Tissue” (Japanese Ministry of Health,
Labour and Welfare Notiﬁcation No. 0208003), was published in
February 2008, and the allogeneic-cell guideline, entitled
“Guideline on Ensuring the Quality and Safety of Products
Derived from the Processing of Allogeneic Human Cells/Tissue”
(Japanese Ministry of Health, Labour and Welfare Notiﬁcation No.
0912006) was published in September 2008. However, the
guidelines dealt with autologous- and allogeneic-cell/tissue-
based products, respectively, in a general manner. Further studies
of critical issues related to the prompt development of products
derived from human stem cells, such as human somatic stem
cells, human ES cells, and human iPS cells, became necessary.
In the ﬁscal year 2008, the Japanese Ministry of Health, Labour
and Welfare convened a panel of experts: “Study Group on
Ensuring the Quality and Safety of Pharmaceuticals and Medical
Devices Derived from the Processing of Human Stem Cells.” The
panel (chaired by Dr. Takao Hayakawa) was established as a sci-
entiﬁc research project of the Ministry of Health, Labour and
Welfare of Japan.
The objective of the study group is to promote the sound
development of products derived from human stem cells by
investigating scientiﬁc and technological advances, ethics, regula-
tory rationale, and international trends in human stem cell-derived
products and to establish and implement appropriate safety eval-
uation criteria.
The early activities of the study group (2008e2010) can be
summarized as follows:
(i) From the scientiﬁc and technological perspective, the group
assessed the current state of and future outlook on the
manufacture and clinical application of cell- and tissue-
based products derived from the processing of human so-
matic stem cells, human ES cells, and/or human iPS cells,
with reference to the most up-to-date research and infor-
mation. In particular, the group presented the results of the
study on sources of human mesenchymal stem cells, the
clinical application (including cellular therapy and gene
therapy) to many types of diseases, perspectives for the
establishment and differentiation of iPS cells and clinical
application of iPS cell-based products, and the current state
of and views on therapeutic tissue engineering and its
practical use in regenerative medicine.
(ii) The contents and signiﬁcance of the existing “Guideline for
Clinical Research Using Human Stem Cells” were analyzed,
and the appropriateness of the Japanese Ministry of Health,
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clinical research was evaluated. This could lead to proposals
of views that should be adopted and future directions that
should be followed.
(iii) Guidelines and meeting reports were also analyzed,
including 2 guidelines published by the Japanese govern-
ment entitled “Guideline on Ensuring the Quality and Safety
of Products Derived from the Processing of Autologous Hu-
man Cells/Tissues” (No. 0208003, issued February 2008 by
the Pharmaceutical and Food Safety Bureau) and “Guideline
on Ensuring the Quality and Safety of Products Derived from
the Processing of Allogeneic Human Cells/Tissues” (No.
0912006, issued in September 2008 by the Pharmaceutical
and Food Safety Bureau); 1 guideline on clinical research
involving stem cells published at the end of 2008 by the
International Society for Stem Cell Research (ISSCR); and
several reports on quality characteristics, preclinical trials,
and monitoring of patients treated with products manufac-
tured using cells derived from ES cells, which were presented
in April 2008 at the 45th Cell Therapy-Gene Therapy
Consultative Meeting held at the U.S. Food and Drug
Administration (US FDA). This led to the identiﬁcation of
important parameters and factors for ensuring the quality
and safety of products derived from human somatic stem
cells, ES cells, and/or iPS cells.
(iv) Information on the organization and operation of the Com-
mittee for Advanced Therapy (CAT), established in 2009 by
the European Medicines Agency (EMA), was collected and
analyzed in order to assess the validity of the Japanese sys-
tem and regulations.
(v) As a result of the analyses and discussions described above in
points (i)e(iv), in accordance with the Pharmaceutical Affairs
Law, and with the clinical application of products derived
from human somatic stem cells, iPS cells, ES cells, and other
cells as the goal, the study group concluded that relevant
guidelines should be tailored to speciﬁc cell sources and
phenotypes (human autologous vs. human allogeneic cells;
somatic stem cells vs. iPS cells vs. ES cells vs. other cells) to
facilitate efﬁcient, effective, and rational research and devel-
opment (R&D). Points to be considered include but are not
limited to technical details, the manufacturing process, char-
acterization, quality control, stability evaluation, and the data
necessary to guarantee the safety and efﬁcacy of the products.
With this perspective in mind and with a desire for consistency
in scientiﬁc principles and concepts, 2 interim reports on draft
guidelines on products derived from the processing of autologous
human somatic stem cells and autologous human iPS cells were
prepared in 2009, on the basis of Japanese Ministry of Health, La-
bour and Welfare Notiﬁcation No. 0208003. Three other interim
reports on draft guidelines on products derived from the processing
of allogeneic human somatic stem cells, allogeneic human iPS cells,
and human ES cells, respectively, were also prepared, on the basis of
Japanese Ministry of Health, Labour and Welfare Notiﬁcation No.
0912006. These 5 sets of draft guidelineswere thoroughly discussed
from a variety of viewpoints. They were then widely circulated
among interested parties as articles in a relevant scientiﬁc journal to
allow readers to comment (Hayakawa T., et al.: Journal of the Jap-
anese Society for Regenerative Medicine, 9, 116e180 [2010], in
Japanese). Thereafter, these paperswere updated andpublished as 8
articles (Hayakawa T., et al.: Journal of the Japanese Society for
Regenerative Medicine, 10, 86e152 [2011], in Japanese) that served
as the basis for the ﬁnal draft guidelines. After extensive discussions
with the study group and after public consultation, the Pharma-
ceutical and Food Safety Bureau of the Japanese Ministry of Health,Labour and Welfare issued 5 notiﬁcations on September 7, 2012
entitled “Guideline on Ensuring the Quality and Safety of Pharma-
ceuticals and Medical Devices Derived from the Processing of
Autologous Human Somatic StemCells,” “Guideline on Ensuring the
Quality and Safety of Pharmaceuticals and Medical Devices Derived
from the Processing of Allogeneic Human Somatic Stem Cells,”
“Guidelines on Ensuring the Quality and Safety of Pharmaceuticals
and Medical Devices Derived from the Processing of Autologous
Human Induced Pluripotent Stem(-Like) Cells,” “Guidelines on
Ensuring the Quality and Safety of Pharmaceuticals and Medical
Devices Derived from the Processing of Allogeneic Human Induced
Pluripotent Stem(-Like) Cells,” and “Guidelines on Ensuring the
Quality and Safety of Pharmaceuticals and Medical Devices Derived
from the Processing of Human Embryonic Stem Cells.”
Because these ofﬁcial notiﬁcations were written in Japanese, we
translated them into English in order to introduce them to relevant
international societies. The English versions were produced via free
translation so that the concepts in the original Japanese versions
could be interpreted as precisely as possible.
In this paper, we introduce guidelines that describe the basic
technological requirements for ensuring the quality and safety of
pharmaceuticals andmedical devices derived from theprocessingof
autologous human somatic stem cells. There may be cases where
certain ﬁnal products derived from the processing of somatic stem
cells that are multipotent and retain the ability to self-replicate may
be used in a nonhomologous manner, even if they are autologously
derived. In other words, as a result of cell processing, the product
could exhibit cell characteristics different from those of the starting
cells, and the product might be applied and function at a site (cell
environment) different fromwhere the original cells were localized.
Concerns related to these points have been added to Notiﬁcation No.
0208003, which serves as a basis for the present guideline.
Before interpreting and implementing the present guideline, the
following should be taken into consideration. The ultimate goal is
to provide patients with new therapies that utilize regenerative
medicine. The role of the guideline is to present the scientiﬁc
principles, concepts, ideas, and technical elements that will achieve
the speciﬁed goal in the most efﬁcient and effective manner
possible. Because a wide variety of products is anticipated,
encompassing a variety of situations and circumstances, the
guideline describes comprehensive points of concern. Therefore, it
is important to identify the relevant testing parameters and eval-
uation methods by taking into consideration, for example, the
characteristics of the cells in question, the speciﬁc clinical objective,
and the method of application. Those that are applicable should be
justiﬁed and implemented in an appropriate and ﬂexible manner.
Several points should be kept in mind with respect to the
development of medicinal products for regenerative medicine and
the implementation of this guideline. The desired products are
expected to show a potential as a novel therapeutic method as a
result of relevant proof of concept (POC) and relevant data and/or
information, showing no critical concerns about product safety that
might impede the use of the product in humans for the ﬁrst time.
Thorough observance of the Declaration of Helsinki, including
proper informed consent and right of self-determination on the
part of the patient, is indispensable.
It should be emphasized again that the primary goal of our
endeavor is to offer suitable medical opportunities as quickly as
possible to patients with severe diseases that are difﬁcult to treat
with conventional modalities. The present guideline should be
useful for this purpose. Therefore, it is important to interpret and
employ the guideline in a ﬂexible and meaningful way. Stringent
observance of the guideline without taking into account the pa-
tients and their speciﬁc situations (which is like putting the cart
before the horse) should be avoided.
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medicine is desirable formaintaining and improving human health.
The development of innovative and revolutionary medicinal
products and therapeutic techniques should beneﬁt our country as
well as the international community. Regenerative medicine is a
great way tomake a peaceful international contribution that will be
a legacy for mankind. In this context, the role of the government is
to promote clinical research and industrialization; regulations and
guidelines are adopted such that we advance towards this common
goal in a scientiﬁc, rational, efﬁcient, and effectivemanner. All those
involved, like players in the same arena with a common goal in
mind, accumulating scientiﬁc data and concentrating wisdom,
should continue to make efforts to deliver these revolutionary cell-
based products and therapeutic techniques to patients as soon as
possible.Guidelines on ensuring the quality and safety of pharmaceuti-
cals and medical devices derived from the processing of autol-
ogous human somatic stem cells
(Notiﬁcation No. 0907-2, issued by Pharmaceuticals and Food
Safety Bureau, Ministry of Health, Labour and Welfare of Japan on
September 7, 2012.)2. Introduction
1. The present guidelines outline basic technical elements for
ensuring the quality and safety of pharmaceuticals and medical
devices derived from the processing of autologous human so-
matic stem cells. These products are hereafter referred to as
autologous human somatic stem cell-based products or simply
as the “desired cell products.”
There are many types of cell products and methods of clinical
application. In addition, the scientiﬁc progress in this ﬁeld is
incessant, while expertise and knowledge are constantly accu-
mulating. Therefore, it is not always appropriate to consider the
present guidelines all-inclusive and deﬁnitive. Consequently,
when testing and evaluating each product, it is necessary to
adopt, on a case-by-case basis, a ﬂexible approach based on
rationale that reﬂects the scientiﬁc and technological advances
at that point in time.
2. The main purpose of evaluating the quality and safety of the
desired cell products before conducting investigational clinical
trials (e.g., at the time of “clinical trial consultation”) is to
determine whether there are any quality and/or safety prob-
lems that would obviously hinder initiation of human clinical
trials of the autologous human somatic stem cell-based prod-
ucts in question, whether certain quality attributes (QA) of the
product are understood sufﬁciently to establish a relationship
between the clinical ﬁndings and the QA, and whether con-
sistency of the QA can be ensured within a deﬁnite range.
Simultaneously, it is important to eliminate as much as
possible any known risk factors associated with product
quality and safety using up-to-date science and technology and
to describe the scientiﬁc appropriateness of the results of such
an action. The remaining presumed risk factors should be
weighed against the risks associated with not performing the
trials on patients who suffer from diseases that are serious and
life-threatening or that involve marked functional impairment
or a marked decrease in quality of life (QOL) resulting from the
loss of a certain degree of a physical function or form, or for
which existing therapies have limitations and do not result in acure. Furthermore, it is important to entrust the patient with
the right to make a decision after receiving all of the available
information. When applying for approval of investigational
clinical trials, applicants can submit a provisional nonclinical
data package, which is prepared rationally by taking into ac-
count product aspects and patient aspects including a balance
between the risk of the product vs. the risk facing the patient
with/without treatment in question, in order to decide to
initiate investigational clinical trials, on the premise that the
data package submitted at the time of marketing authorization
application/registration to ensure quality and safety will be
enriched and developed in line with the guidelines as the
clinical trial progresses.
Finally, applicants are encouraged to discuss with the Phar-
maceuticals and Medical Devices Agency (PMDA) the type and
amount of data that may be needed to initiate an individual
clinical trial. Because of differences in product origin, target
disease, target patients, application sites, application methods,
and processing methods, there may be numerous variations
among individual data packages; these differences cannot be
deﬁnitively clariﬁed in the present guidelines.
3. The items, test methods, criteria, and any other technical re-
quirements described in the present guidelines are intended to
be considered, selected, applied, and evaluated to serve each
intended purpose; they do not necessarily require the most
stringent level of interpretation and practice. Applicants are
encouraged to explain and provide justiﬁcation for any
consideration regarding the background, selection, applica-
tion, and the content as well as the extent of the evaluation
that are appropriate for their own purpose and are scientiﬁ-
cally valid.3. Chapter I. General principles
3.1. Objective
The present guidelines outline basic technical elements for
ensuring the quality and safety of pharmaceuticals and medical
devices derived from the processing of autologous human somatic
stem cells (excluding allogeneic somatic stem cells). These products
are hereafter referred to as autologous human somatic stem cell-
based products or simply as the “desired cell products.”
3.2. Deﬁnitions
The deﬁnitions of the technical terms used in this guideline are
as follows:
1. “Human somatic stem cells”: Cells that are collected from
humans or cells that are derived from such cells through cell
division and that possess multipotency and maintain the
ability to self-renew or a similar ability. In other words, tissue
stem cells (e.g., hematopoietic stem cells, neural stem cells,
mesenchymal stem cells [including bone marrow stromal
stem cells and adipose-tissue-derived stem cells], corneal
stem cells, skin stem cells, hair follicle stem cells, intestinal
stem cells, hepatic stem cells, and skeletal muscle stem cells)
or cell groups that have abundant populations of these cells
(e.g., whole-bone-marrow cells that include hematopoietic
stem cells), including vascular precursor cells, umbilical cord
blood, and bone marrow stromal cells. “Human somatic stem
cells” also include cells obtained by culturing these cells
in vitro. Human embryonic stem (ES) cells, human induced
T. Hayakawa et al. / Regenerative Therapy 2 (2015) 57e69 61pluripotent stem (iPS) cells, human induced pluripotent stem-
like (iPS-like) cells, human embryonic germ (EG) cells, human
multipotent germline stem (mGS) cells, human partheno-
genesis stem cells, human nuclear transplant stem cells, hu-
man cancer cells, human cancer stem cells, and cells derived
from these cells are not included. (Note: The deﬁnitions of
human ES cells, human iPS cells, and human iPS-like cells are
provided in other guidelines, particularly, in “Guidelines on
Ensuring the Quality and Safety of Pharmaceuticals and
Medical Devices Derived from the Processing of Human ES
Cells” and “Guidelines on Ensuring the Quality and Safety of
Pharmaceuticals and Medical Devices Derived from the Pro-
cessing of Allogeneic/Autologous Human iPS(-like) Cells,”
respectively.)
2. “Processing of cells and tissues”: Any processing of a cell type or
tissue, such as propagation and/or differentiation, production of
a cell line, activation of a cell by pharmaceutical or chemical
treatment, alteration of a biological characteristic, combination
with a noncellular component, and manipulation using genetic
engineering, with the aim of preparing desired cell products to
treat a patient or repair or regenerate a tissue.
Isolation of a tissue, homogenization of a tissue, separation of
cells, isolation of a speciﬁc cell, treatment with antibiotics,
washing, sterilization by g-irradiation or other methods,
freezing, thawing, and other such procedures that are regarded
as minimal manipulations are not considered “processing.”
3. “Manufacture”: Actions undertaken before the ﬁnal product (an
autologous human somatic stem cell-based product) is released
to themarket. This includes, in addition to the processing of cells
and tissues, minimal manipulations such as separation of a tis-
sue, homogenization of a tissue, separation of cells, isolation of a
speciﬁc cell, treatment with antibiotics, washing, sterilization by
g-irradiation or other methods, freezing, thawing, and other
procedures that do not change the original properties of the
cells or tissues.
4. “Phenotype”: A morphological or physiological characteristic
that is produced by certain genes under deﬁned environmental
conditions.
5. “Donor”: A person who donates his/her own cells or tissue,
which serve as a raw material for an autologous human somatic
stem cell-based product. For such a product, a patient is deﬁ-
nitely a donor. (Note: A patient is identiﬁed as a donor for actual
treatment. It is also presumed that cells/tissues obtained from a
donor other than the patient are used for the purpose of test
production during R&D stages.)
6. “Transgenic construct”: A construct that contains a vector for
introducing a target gene (a speciﬁc gene encoding a desired
protein or RNA) into a target cell, the target gene itself, and the
coding sequences of the elements essential for the expression of
the target gene.4. Chapter II. Manufacturing methods
Describe all important and relevant information concerning the
manufacturing method, taking into account the items listed below.
This information will help ensure the quality, safety, and efﬁcacy of
the ﬁnal products, and it is important for guaranteeing consistency
in quality from the manufacturing perspective. It should be noted
that quality, safety, and consistency are ensured by mutual com-
plementary measures throughout the manufacturing process. It is
very important that the measures be rational and that they serve
the intended purpose. It is acceptable to omit a portion of the items
listed below if the quality, safety, and constancy of the ﬁnal prod-
ucts can be established by suitably chosen quality tests, control ofthe ﬁnal or intermediate products, or control of the manufacturing
process.4.1. Raw materials and materials used in manufacturing
1. Human cells and tissues used as raw materials
(1) Features of biological structure and function, selection
criteria
Provide and explain the reasons for selecting the cells
and tissues used as raw materials, with reference to the
characteristics of their biological structure and function,
such as morphological characteristics, growth charac-
teristics, biochemical indicators, immunological in-
dicators, speciﬁc substances produced, and other
suitably chosen and appropriate genotype or phenotype
indicators (or markers). In particular, demonstrate that
the somatic stem cells used as a raw material possess
clinically useful stemness. Stemness in this case does not
necessarily indicate the potential for multilineage dif-
ferentiation but refers to the ability to differentiate into
cells that have an expected function in vivo. In addition,
although demonstrating the differentiation in vitro is
desirable, it may sufﬁce to show differentiation in vivo if
a rational explanation is provided. For example, when
using myocardial stem cells, which are somatic stem
cells, as a raw material, it is acceptable to show that
myocardial stem cells can differentiate into car-
diomyocytes. This should lead to the identiﬁcation of the
main cell characteristics that will be employed when
applying cells to the treatment of a patient.
It is acceptable to perform tests using test specimens
obtained from a donor other than the patient at the
research and development stages before the beginning of
a clinical trial. In any case, it is recognized that quanti-
tative limits and technological limits on sample analysis
will affect the extent to which such studies can be
performed.
(2) Considerations with respect to the donor
To ensure the safety of patients, the personnel involved
in manufacturing the product, and the healthcare
workers who treat patients, establish test parameters by
which to assess possible infection of the cells and/or
tissues and provide justiﬁcation for the parameters.
Special consideration should be given to hepatitis B virus
(HBV), hepatitis C virus (HCV), human immunodeﬁciency
virus (HIV), and human T-lymphotropic virus (HTLV).
Establish eligibility criteria that take into consideration
the genetic characteristics, medical history, and the
health condition of the patient among other parameters
and provide justiﬁcation for the use of the patients as
donors. Donor genomic or gene analysis shall be per-
formed in accordance with “Ethical Guidelines for
Analytical Research on HumanGenome and Gene” issued
jointly on February 8, 2013, and partially revised on
November 25, 2014, by the Japanese Ministry of Educa-
tion, Culture, Sports, Science and Technology; Ministry of
Health, Labour and Welfare; and the Ministry of Econ-
omy, Trade and Industry.
(3) Records related to the donor
Complete records related to the donor should be
retained in order to obtain any information necessary to
make sure that the safety of cells and tissues used as raw
materials can be veriﬁed. Concrete measures shall be
described. For patients and donors of test samples, it is
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that is related to the intended use of the cells.
(4) Collection, storage, and transport of cells and tissues
(i) Eligibility of personnel and medical institutions
collecting the samples
Describe the technical requirements for
personnel and medical institutions that collect the
cells and tissues.
(ii) Suitability of the sampling site and sampling
method
Describe the rationale for selecting the cell and
tissue sampling sites and the sampling method.
State why the selected sites are scientiﬁcally and
ethically appropriate. For cell and tissue sampling
methods, indicate the suitability of the equipment
and drugs used and the measures adopted to pre-
vent microbial contamination, erroneous sampling
(mix-up), and cross-contamination.
(iii) Informed consent from donors
Describe the details of the informed consent
from donors of the cells and/or tissues.
(iv) Protection of donor privacy
Indicate the measures adopted to ensure the
protection of the donor's privacy.
(v) Tests to ensure donor safety
If tests such as those to conﬁrm the state of the
sampling site need to be performed in order to
ensure the safety of the donor at the time of cell or
tissue sampling, describe the details of the tests as
well as any interventions undertakenwhen the test
results indicate that a problem exists.
(vi) A storage method and measures to prevent erro-
neous sampling (mix-up)
If the cells and/or tissues need to be stored for a
deﬁnite period of time, set the storage conditions
and storage period and provide the justiﬁcation.
Describe in detail the measures to be taken to
prevent erroneous sampling (mix-up).
(vii) Transportation methods
If cells and/or tissues need to be transported,
specify the containers used for transport and the
transportation procedure (including temperature
control) and provide the justiﬁcation.
(viii) Preparation of records and record-keeping pro-
cedures
Prepare written records for items (i) through (vii)
above and describe the record-keeping procedures
in detail.2. Raw materials other than the target cells and tissues, mate-
rials used in manufacturing
Describe raw materials other than the target cells and/or
tissues as well as materials used in the manufacturing pro-
cess; indicate their appropriateness for the intended use;
and, if necessary, establish their speciﬁcations (a set of
acceptance criteria and analytical procedures). Proper quality
control of these materials should be implemented.
When so-called Biological Products or Speciﬁc Biological
Products (refer to Articles 2.9 and 2.10 of the Pharmaceu-
tical Affairs Law) are used as raw materials, use the mini-
mum amount required and strictly conform to the relevant
laws and regulations, such as “Standards for Biological Raw
Materials” (Notiﬁcation No. 210, Japanese Ministry of
Health, Labour and Welfare, 2003; a partially revised
version was issued on September 26, 2014). It is particu-
larly important to adequately evaluate information relatedto the inactivation and elimination of viruses and to specify
measures for encouraging retrospective survey and other
studies.
(1) When culturing cells(i) Indicate the appropriateness of all media compo-
nents including such as additives (e.g., serum,
growth factors, and antibiotics), and reagents used
in the treatment of cells and set speciﬁcations if
necessary. Give consideration to the route of clinical
application and other parameters of the ﬁnal
product when setting speciﬁcations concerning the
appropriateness of each component.
(ii) Take into consideration the following points with
respect to media components:
(a) The ingredients and water used inmedia should
be of high quality and high biological purity, and
their quality should be controlled using stan-
dards equivalent to those used with pharma-
ceuticals and pharmaceutical ingredients.
(b) Provide information on all ingredients in the
media as well as the rationale for their selection,
and, if necessary, the quality control and other
procedures. However, widely known and
commercially available media products such as
DMEM,MCDB, HAM, and RPMI are regarded as a
single raw-material set.
(c) Conduct sterility tests and performance tests on
media that contain all components in order to
determine whether they are suitable as target
media. Set speciﬁcations for any other relevant
parameters thought to be controlled in the
process and perform proper quality control.(iii) Heterologous serum or components derived from
heterologous or homologous serum shall not be
used unless they are essential for processes such as
cell activation or cell growth. In particular, for
products thatmaybe used repeatedly, investigate, to
the extent possible, ways to avoid using these serum
components. If the use of serum or other such ma-
terials is unavoidable, consider the following points
and investigate ways to prevent the contamination
and the transmission of bacteria, fungi, viruses, and
prions from serum and other related materials as
well as treatment methods for their elimination, to
the extent possible, from the ﬁnal product.
(a) Clarify the origin of the serum or other
components.
(b) Make strenuous efforts to minimize the risk of
prion infection, e.g., by strictly avoiding the use
of serum from areas or regions with known
outbreaks of bovine spongiform encephalopa-
thy (BSE).
(c) Use these batches of serum only after conﬁrm-
ing that they are not contaminated with viruses
or other pathogens by conducting appropriate
tests to prove the absence of speciﬁc viruses and
mycoplasma that originate in animal species.
(d) Perform appropriate procedures to inactivate
and eliminate bacteria, fungi, and viruses to an
extent that does not affect activation and
growth of the cells. For example, to avoid the
risks associated with latent viral contamination,
perform combinations of heat treatment,
ﬁltration, g-irradiation, and/or ultraviolet light
treatment if needed.
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in order to monitor cultured cells for viral in-
fections, to monitor onset of viral diseases
among the patients, and measure antigen pro-
duction in response to a component of the
heterologous serum used.(iv) When using feeder cells, conduct quality evalua-
tion while referring to “Derivation and Charac-
terisation of Cell Substrates Used for the
Production of Biotechnological/Biological Prod-
ucts” (Pharmaceutical Notiﬁcation No. 873, issued
July 14, 2000, Evaluation and Licensing Divison,
Pharmceuical and Food Safety Bureau, Japanese
Ministry of Health, Labour and Welfare), “Guide-
lines on Public Health Infection Issues Accompa-
nying Xenotransplantations” (Notiﬁcation No.
0709001, issued July 9, 2002, Research and
Development Division, Health Policy Bureau,
Japanese Ministry of Health, Labour and Welfare),
and “Guidelines on Epithelial Regenerative Ther-
apy Using 3T3J2 Strain or 3T3NIH Strain Cells as
Feeder Cells” based on “Guidelines on Public
Health Infection Issues Accompanying Xeno-
transplantations” (Notiﬁcation No. 0702001, is-
sued July 2, 2004, Research and Development
Division, Health Policy Bureau, Japanese Ministry
of Health, Labour and Welfare) in order to prevent
contamination of feeder cells and the trans-
mission of bacteria, fungi, viruses, and prions.
Indicate the methods for the inactivation of cell
division potential and conditions such as cell
density when using the feeder cells. However, if,
for example, the feeder cells or equivalent cells
are being used in the manufacture of a cell or
tissue product that has already been used clini-
cally and whose characteristics and microbiolog-
ical safety have already been assessed and
conﬁrmed, it is possible to omit the virus tests or
parts of other tests by demonstrating the appro-
priateness of these cells.
(v) Avoid the use of antibiotics as much as possible.
However, if the use of antibiotics at the initial stages
of processing is deemed indispensable, attempt to
decrease their use at subsequent steps as much as
possible, and clearly state the appropriateness of
their use from perspectives such as the scientiﬁc
rationale, estimated residual amounts in the ﬁnal
product, and the effects on the patient. If it has been
determined that an antibiotic can be adequately
eliminated, its use does not need to be restricted. On
the other hand, if a patient has a history of allergy to
the antibiotic used, in principle, this therapeutic
method should not be used. If there is no way to
avoid the use of antibiotics, administer the ﬁnal
product in question very carefully and obtain
informed consent from the patient.
(vi) If growth factors are used, show the appropriate
quality control methods using relevant parameters,
such as purity and potency, for which established
acceptance criteria and assay methods are
employed, in order to guarantee the reproducibility
of the cell culture characteristics.
(vii) For media components and other components that
are used in processing and that may contaminatethe ﬁnal product, choose components that do not
have any harmful biological effects.(2) When combining cells with noncellular components
(i) Quality and safety of noncellular raw materials
If the ﬁnal product consists of cells and noncel-
lular components, such as a matrix, medical mate-
rials, scaffolds, support membranes, ﬁbers, and
beads, describe in detail the quality and safety of the
noncellular components.
Provide any relevant information concerning the
noncellular raw materials, taking into consideration
their type and characteristics; the form and function
in the ﬁnal product; and evaluation of their quality,
safety, and efﬁcacy from the standpoint of the pre-
sumed clinical indication. If using materials that are
absorbed by the body, perform the necessary tests
on the degradation products to address safety con-
cerns.
With respect to the tests that should be carried
out, refer to “Basic Views on Biological Tests Neces-
sary for Regulatory Approval for Manufactured or
Imported Medical Devices” (Notiﬁcation No.
0213001, issued February 13, 2003, Pharmaceutical
and Food Safety Bureau, Japanese Ministry of Health,
Labour and Welfare), describe the test results, and
provide justiﬁcation for the use of such raw mate-
rials. The use of information from scientiﬁc literature
is encouraged.
(ii) Interactions with target cells
Demonstrate the validity of the tests used and
provide justiﬁcation for the results obtained for
the following 3 items with respect to the in-
teractions between noncellular components and
cells in the ﬁnal product and in any intermediate
products.
(a) The noncellular components do not have any
deleterious effects on the function, growth ca-
pacity, activity, or stability of the cells in the ﬁnal
product required for the presumed clinical
indication or the cells in any intermediate
products.
(b) Evaluate to the extent possible any potential
interactions between the cells and noncellular
components, taking into consideration, for
example, the mutation, transformation, and/or
dedifferentiation of the cells in the ﬁnal product
or cells in intermediate products.
(c) Show that there is no loss of the expected
properties of the noncellular components for the
presumed clinical indication as a result of any
interactions between the noncellular compo-
nents and the cells in the ﬁnal and intermediate
products.(iii) When using noncellular components to isolate the
desired cell products from the application site
When using noncellular components with the
objective of segregating the desired cell products
from the application site, conﬁrm their usefulness
and safety by referring to items (a) through (d)
below.
(a) Membrane permeability kinetics and the phar-
macological effects of target physiologically
active substances derived from the cells in the
ﬁnal product.
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tory products.
(c) Effects of noncellular components on the area
near the application site.
(d) When a pharmacological effect of a target
physiologically active substance derived from a
desired cell product is anticipated and the
objective is segregation of the application site
and the desired cell product or undifferentiated
cells, conﬁrm that the cells do not leak out,
which might result, for example, from the
degradation of noncellular components.(3) When cells are subjected to genetic engineering
When genes are introduced into cells, provide the
following details:
(i) For the target gene (the speciﬁc gene encoding a desired
protein or RNA), information related to its structure and
origin, the method by which it was obtained, cloning
methods, and methods of cell bank preparation, control,
renewal, and other relevant information.
(ii) Nature of the transgene.
(iii) Structure, biological activity, and properties of the
desired protein or RNA derived from the target gene
(iv) All raw materials, their properties, and procedures
(transgenic method, origin and properties of the vector,
and method for obtaining the vector used for introduc-
tion of the transgene) needed to produce the transgenic
construct.
(v) Structure and characteristics of the transgenic construct.
(vi) Control and preparation methods for cell and virus
banks that are used to prepare vectors and transgenic
constructs.For manufacturing methods for transgenic cells, refer to Chapter
2 and other sections of “Guidelines for Ensuring the Quality and
Safety of Gene Therapy Pharmaceuticals,” which is an appendix in
“Concerning Guidelines for Ensuring the Quality and Safety of Gene
Therapy Pharmaceuticals” (hereafter referred to as “Gene Therapy
Pharmaceutical Guidelines”), published as Notiﬁcation No. 1062 by
Pharmaceutical Affairs Bureau, Japanese Ministry of Health and
Welfare on November 15, 1995. In addition, state the appropriate-
ness of the establishment of a cell line in accordance with the ap-
pendix of the same notiﬁcation.
On the basis of the law (Law No. 97, 2003) implemented to
ensure biodiversity by regulating the use (and other aspects) of
genetic recombination-derived organisms, a separate application
procedure for evaluation will be required when living organisms,
including certain cells, “viruses,” and “viroids,” are genetically
modiﬁed. The following cells are not regarded as living organisms:
“human cells” or “cells that have the ability to differentiate, or
differentiated cells that are not viable when alone under natural
conditions.”
Regardless of the guidelines mentioned above, if a gene intro-
duced into cells is used as a reagent in the manufacturing process
and does not contribute either chemically or functionally to the
ﬁnal product, it is acceptable to describe, on the basis of current
knowledge, how the quality and safety of the gene conform to the
intended use.4.2. Manufacturing process
When manufacturing autologous human somatic stem cell-
based products, describe in detail the manufacturing method andverify, to the extent possible, the appropriateness of the method,
using the items listed below, in order tomaintain consistency in the
quality of the product.4.2.1. Lot control
Indicate whether a lot control procedure is applied for ﬁnal
products and intermediate products. If any lot control is adopted,
establish standardized procedures for the makeup and control of
the lot, which may include the lot size, labeling/numbering, testing
method and acceptance criteria.4.2.2. Manufacturing method
Provide an outline of the manufacturing method, from the
receipt of the cells and tissues to be used as raw materials to the
isolation of somatic stem cells and the establishment of the ﬁnal
product. Describe the technical details of the process and necessary
process control and product quality control.
(1) Test upon receipt
Establish a battery of tests as well as acceptance criteria for
assessing the suitability of the cells and tissues that will serve as the
raw materials, taking into account the nature of the cells and their
intended use. These may include, for example, visual tests, micro-
scopic examination, recovery factors of target cells, cell viability
assays, characterization of cells and tissues, and microbiological
tests. At the stage of initiating clinical trials, provide the actual
measured values obtained up until that point with test samples,
and propose a provisional set of acceptance criteria based on these
values.
(2) Inactivation and elimination of bacteria, fungi, viruses, and
other microorganisms
In cells and tissues that serve as raw materials, inactivate and
eliminate bacteria, fungi, viruses, and other microorganisms, if
necessary and whenever possible, to the extent possible without
changing the cellular characteristics (e.g., cell viability, phenotype,
genetic traits, and speciﬁc functions) and quality of the cells and
tissues serving as raw materials. State the appropriateness of the
measures, procedures, and evaluation methods used, if any.
(3) Tissue homogenization, cell separation, isolation of speciﬁc
cells, and other techniques
Describe methods for homogenization of tissues, separation of
cells, and isolation of somatic stem cells as well as methods for
washing of the cells and tissues (and other methods), that are
performed at the early stages of manufacturing of somatic stem
cell-based products from collected cells and tissues. When isolating
the speciﬁc somatic stem cells, establish methods of cell
identiﬁcation.
(4) Preparation of cells that are a principal component and active
ingredient in the ﬁnal product
Describe the methods used to collect human cells and tissues, to
isolate somatic stem cells, and to obtain the cells that serve as the
active ingredient in the ﬁnal product. The items to be described
include induction of differentiation, isolation, and culture of the
desired cells, preparation of the media, culture conditions, the
culture period, and the yield of the cells at each step. Describe the
appropriateness of each method.
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When a cell bank is established at any stage during the manu-
facture of autologous human somatic stem cell-based products,
describe the rationale for preparing the cell banks; the methods
used to prepare the cell banks; the characteristics of the cell banks;
and the storage, maintenance, control, and renewal methods as
well as any other processes and tests performed. Provide justiﬁ-
cation for each. Refer to “Derivation and Characterisation of Cell
Substrates Used for the Production of Biotechnological/Biological
Products” (Pharmaceutical Notiﬁcation No. 873, issued July 14,
2000, Japanese Ministry of Health, Labour and Welfare) and other
documents. However, it is acceptable to omit a portion of the study
items, if there is plausible evidence that the cells are of autologous
origin.
(6) Measures to prevent erroneous sampling (mix-up) and
cross-contamination during the manufacturing process
It is extremely important to prevent erroneous sampling and
cross-contamination during the manufacturing process when
manufacturing the autologous human somatic stem cell-based
products. Therefore, describe preventive measures in the process.
4.2.3. Characterization of cells that are a principal component and
active ingredient in the ﬁnal product
For such cells, analyze the attributes, such as cell population
purity (to control contamination by nontarget cells), cell viability,
morphological characteristics, cell growth characteristics,
biochemical markers, immunological markers, distinctive sub-
stances produced by the cells, karyotype, and other appropriate
genotypic and phenotypic markers. In addition, characterize their
biological functions, if necessary. Furthermore, to evaluate the
appropriateness of the culture duration and the stability of the
cells, use appropriate markers of cell characteristics to demonstrate
that there have been no unintended changes in cells cultured
longer than the proposed culture period. It is acceptable to perform
these studies using test samples obtained from donors who are not
patients in place of the products that will be prepared for a clinical
trial. On the basis of these test results, identify the critical cell
characteristics that should be used when applying the product to a
patient. Although comprehensive cell characterization is always
desirable, it is not always possible to characterize the cells fully
because there are quantitative and technological limits on sample
analysis. Thus, it is acceptable to perform a limited study to the
extent possible. When cell processing, such as growth within the
body, is anticipated after the application, clearly demonstrate the
functions expected by describing the speciﬁed criteria with respect
to the passage number or number of cell divisions.
4.2.4. The form and packaging of the ﬁnal product
The form and packaging of the ﬁnal product shall ensure the
quality of the ﬁnal product.
4.2.5. Storage and transport of the ﬁnal product
If an intermediate or ﬁnal products need to be stored and
transported, the storage procedure and duration, the containers
used for transport, and the transportation procedure (including
temperature control) shall be stated and their suitability clearly
indicated (refer to Chapter III).
4.2.6. Consistency of the manufacturing procedure
To assess the consistency of the manufacturing process using
each product (or each lot if any) obtained from different pro-
duction runs, determine whether they differ signiﬁcantly withrespect to the number of cells, cell viability, and cell character-
istics (such as relevant markers of a phenotype and genotype,
functional characteristics, and the percentage of the desired
cells) and from the point of view of the clinical application
method and the intended clinical use of the product. It is
acceptable to use test samples obtained from donors who are not
patients in place of the products that will be prepared for the
clinical trial. Evaluation of intermediate products may provide
insight into the suitability of cells and tissues for use as raw
materials and the validity of the manufacturing process up until
the intermediate-product stage and can provide an appropriate
guidepost en route to the ﬁnal product. Therefore, it may be
reasonable to adopt such an approach, where necessary and
appropriate.
When the manufacturing process involves long cryopreserva-
tion periods or cell cultivation periods, perform sterilization
tests at constant intervals to conﬁrm that sterility has been
maintained.
4.2.7. Changes in the manufacturing process
If the manufacturing method is altered at some point during
development, and the test results that are obtained using products
manufactured before the change in the manufacturing method are
to be used in the application for clinical-trial or regulatory approval,
demonstrate that the products manufactured before and after the
change to the manufacturing process are comparable.
4.3. Quality control of the ﬁnal product
4.3.1. Introduction
The overall quality control strategy for products manufactured
using human somatic stem cells includes speciﬁcations (a set of
acceptance criteria and analytical procedures) for the ﬁnal prod-
ucts, quality control of raw materials for each therapeutic applica-
tion to each patient, veriﬁcation of the appropriateness of the
manufacturing process, maintenance of consistency, and proper
quality control of any intermediate products.
Speciﬁcations will differ among ﬁnal products, depending on
the type and properties of the desired cells and tissues,
manufacturing methods, intended clinical use, method of clinical
application, stability, and test methods. These differences shall be
taken into consideration when setting the acceptance criteria and
test procedures. In addition, speciﬁcations shall be set and justi-
ﬁed from the standpoint of achieving the purpose of quality
control as a whole, by taking into consideration the mutually
complementary relationships among 1) the veriﬁcation of the
suitability of the manufacturing process, 2) the method for
maintaining consistency, and 3) quality control of the raw mate-
rials and intermediate products. The purpose of the assessment at
the initiation of clinical trials is to conﬁrm that the product in
question is unlikely to pose signiﬁcant quality/safety problems for
use in investigational clinical trials. Therefore, it is possible to set
provisional speciﬁcations with allowance for some variation on
the basis of the measured values obtained for a few test speci-
mens, as long as one can explain about the relationship between
the results of clinical tests and the quality attributes after the
clinical trial. However, testing for sterility and the absence of
mycoplasma is essential. It should be noted that the quality control
strategy, including speciﬁcations, should be enriched and devel-
oped as the clinical trial progresses.
4.3.2. Quality control of the ﬁnal product
Refer to the general quality control parameters and tests shown
below, set necessary and appropriate speciﬁcations for the ﬁnal
product, and provide the rationale for the speciﬁcations set.
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not make up a lot and for products that do make up a lot because
normally each lot is the unit subject to quality control.
(1) Cell number and cell viability
For cells that are an active ingredient in the ﬁnal product,
determine the cell number and viability in the ﬁnal product or, if
needed, in an appropriate intermediate product. At the beginning
of the clinical trial, it is acceptable to set provisional acceptance
criteria that are based on measured values obtained for a small
number of test samples.
(2) Tests of identity
Conﬁrm that the intended target cells comprise the product by
assessing important cell characteristic(s), such as morphological
characteristics, biochemical markers, immunological markers,
characteristic products, and other appropriate genotypes or
phenotypes.
(3) Tests of purity
To test the purity of the cell population in a ﬁnal product, if
necessary, set the test parameters, test methods, and acceptance
criteria for evaluating and controlling nontarget cells, such as un-
differentiated cells, cells that exhibit abnormal growth, trans-
formed cells, and contaminating cells, taking into consideration
such parameters as the origin of the target cells and tissues, the
culture conditions, other parameters of the manufacturing process,
and quality control of intermediate products. At the beginning of
the clinical trial, it is acceptable to set provisional acceptance
criteria that are based on measured values obtained for a small
number of test samples.
(4) Tests for cell-derived, undesirable physiologically active
substances
Specify appropriate tests for determining the permissible dose
limits of any potential undesirable physiologically active substances
that are derived from the target cells if the presence of such sub-
stances in the product is presumed to clearly affect the safety of the
patient. At the beginning of the clinical trial, it is acceptable to set
provisional acceptance criteria that are based on measured values
obtained for a small number of test samples.
(5) Tests for process-related impurities
For substances that may be present in the ﬁnal product as, for
example, contaminants, residues, newly generated products or
degradation products; that potentially originate from raw mate-
rials, noncellular components, media ingredients (including feeder
cells), chemical reagents, or any other process-related materials;
and that may have deleterious effects on quality and safety (for
example, albumin derived from fetal calf serum and antibiotics), it
is necessary to 1) prove that the substance is not present in the ﬁnal
product by taking into consideration the results of process evalu-
ations related to the elimination of the substance or the results of
in-process substance control or 2) establish appropriate tests to
control permissible levels of the substance in the ﬁnal product.
When selecting substances to be tested and setting their accep-
tance criteria, their suitability should be explained and justiﬁed. At
the beginning of the clinical trial, it is acceptable to set provisional
acceptance criteria that are based on measured values obtained for
a small number of test samples.(6) Sterility tests and tests for the absence of mycoplasma
Sterility should be ensured throughout the entire manufacturing
process by evaluating test samples. The sterility (negative results of
tests for common bacteria and fungi) of the ﬁnal product should be
demonstrated before its use in a patient. Appropriate tests con-
ﬁrming the absence of mycoplasma should also be performed. A
validated nucleic-acid ampliﬁcation test can be used. If the results of
sterility and other tests on the ﬁnal product can be obtained only
after the product is administered to the patient, methods for dealing
with the lack of sterility detected after administration should be
established beforehand. In such cases, demonstrate by testing that
the intermediate products are sterile and that sterility has been
strictly maintained in all processes leading to the ﬁnal product. If a
product from the same facility and same process has already been
used in patients, its sterility must be conﬁrmed by testing all pa-
tients. If complete closure (hermetic seal) of a product that is a partof
a lot hasbeenensured, tests on representative samples are sufﬁcient.
When each different application needs to be tested and if test results
can be obtained only after administration to the patient, the decision
to administer the product will be based on the most recent data.
However, even in such cases, the ﬁnal product shall be tested.
It is desirable that every effort be made to avoid the use of anti-
biotics in cell culture systems. However, if antibiotics are used, adopt
measures to ensure that they do not inﬂuence the sterility tests.
(7) Endotoxin test
Perform theendotoxin test, taking into consideration the impactof
the contaminant in the samples. The acceptance criteria do not
necessarily depend on the actual measured values. Set acceptance
criteria by taking into consideration the safety ranges in the Japanese
Pharmacopoeia and/or any other relevant compendia that are based
on a single dose of the ﬁnal product. Endotoxin testing can be estab-
lished asan in-process control test. However, in suchcases, specify the
criteria, including the validation results, and provide the justiﬁcation.
(8) Virus tests
If the absence of HBV, HCV, HIV, and HTLV cannot be demon-
strated at the patient level and these viruses could proliferate in the
cells, use titer tests to detect viruses and conﬁrm that administra-
tion of the stem cell-based products does not adversely affect the
patient. This does not apply if the absence of viruses has been
demonstrated by testing the cell bank or intermediate products. If
components of a biological origin are used in the manufacturing
process, it may be necessary to test the ﬁnal product for viruses
originating from those components. However, whenever possible,
it is preferable to determine that there is no contamination by
testing at the original component stage or by process evaluation.
(9) Speciﬁc biological tests
In some instances, it will be necessary to consider speciﬁc
(quantitative or qualitative) biological testing that takes into ac-
count the cell type, intended clinical use, or distinctive character-
istics of the cells. At the beginning of the clinical trial, it is
acceptable to set provisional acceptance criteria that are based on
measured values obtained for a small number of test samples.
(10) Potency assay
If a speciﬁc physiologically active substance secreted from cells
or tissues contributes to the clinical efﬁcacy or effect of an
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parameters and/or acceptance criteria for the substance in order to
demonstrate the intended effect. Set acceptance criteria for potency
or quantitation of a gene expression product secreted from the cells
when a transgene was introduced. At the beginning of the clinical
trial, it is acceptable to set provisional acceptance criteria that are
based on measured values obtained for a small number of test
samples.
(11) Mechanical compatibility tests
For products that require a certain degree of dynamic strength,
set acceptance criteria for mechanical compatibility and durability
that take into account the site of application. At the beginning of the
clinical trial, it is acceptable to set provisional acceptance criteria
that are based on measured values obtained for a small number of
test samples.
5. Chapter III. Stability of autologous human somatic stem
cell-based products
Taking into full consideration the storage and distribution pe-
riods and the storage form, test the cell viability, potency, and other
characteristics of autologous human somatic stem cell-based
products and/or critical intermediate products to establish stor-
age methods and an expiration date. Provide justiﬁcation for their
suitability. In particular, when product storage and use involves
freezing and thawing, conﬁrm that the freezing and thawing pro-
cesses do not affect the stability or acceptance criteria of the
product. Where necessary and possible, conduct stability studies on
products whose manufacturing period or storage period exceeds
normal periods in order to conﬁrm, to the extent possible, the limits
of stability. This does not apply if a product will be used immedi-
ately after its production.
If an autologous human somatic stem cell-based product will be
transported, the relevant transportation vessels and transportation
procedures (such as thermal management) shall be set and their
appropriateness justiﬁed.
6. Chapter IV. Preclinical safety testing of autologous human
somatic stem cell-based products
To the extent that they are scientiﬁcally reasonable and tech-
nically possible, relevant animal tests and/or in vitro tests may be
performed in order to address safety concerns associated with an
autologous human somatic stem cell-based product. For noncel-
lular constituents and process-related impurities, safety concerns
should be addressed as much as possible by physicochemical an-
alyses not by animal testing.
Testing of human specimens is very valuable, whereas testing
the products of human origin in experimental animals does not
always yield meaningful results. Thus, there may be a scientiﬁc
rationale for preparing products of animal origin and testing them
in appropriate experimental animals, if such a test system is ex-
pected to generate useful results. In such a case, consider using an
animal model that is suitable for the target disease. (For example,
monkeys may be suitable for studies of neurological diseases, and
pigs and/or dogs may be suitable for studies of cardiovascular
diseases.) However, because cells with characteristics identical to
those of cells that constitute an autologous human somatic stem
cell-based product cannot necessarily be obtained from nonhuman
animal species, even if the preparation procedures are the same,
and because a product of animal cell origin manufactured using
identical processes will not necessarily be comparable to a human
cell product, applicants should conduct a feasibility study beforeadopting, conducting, and evaluating such tests. When performing
animal experiments using somatic stem cell-based products ob-
tained from nonhuman animal species, explain why extrapolation
to humans is appropriate. Depending on the case, consider test
systems that employ cells, and clearly explain the suitability of the
test system.
Presented below are items and points to consider and to refer to
when conﬁrming preclinical safety of a product. These examples
are provided for illustration purposes; they are not intended to
prescribe tests for which there is no rational basis. Taking into
consideration the autologous origin of the cells, the characteristics
of the product, the intended clinical use, and other parameters,
conduct necessary and appropriate tests, and evaluate and discuss
the results in a comprehensive manner.
1. For cells expanded beyond the limit set for routine cultivation
(deﬁned by duration of culture, the population doubling level, or
the passage number), demonstrate that alterations other than
those intended have not occurred.
2. It may be necessary to quantify special physiologically active
substances produced by the cells and tissues and to discuss their
effects when they are administered to patients. In some cases,
signiﬁcant amounts of active substances including cytokines
and growth factors would be produced by the cells, potentially
resulting in undesirable effects on the patients.
3. From the standpoint of product safety, examine and discuss the
potential effects of the product on a patient's healthy cells and
tissues and the consequences.
4. Depending on the type of product, investigate and discuss the
possibility of ectopic tissue formation by the cells in the product
and the potential safety consequences thereof when the product
is administered to the patient.
5. Investigate and discuss the possibility of undesirable immuno-
logical reactions caused by the product and/or the expression
product of a transgene and the consequences thereof.
6. Discuss in a comprehensive manner the possibility of tumor
formation, including benign tumors, and/or malignant trans-
formation, taking into consideration the type and characteristics
of the product, number of cells, route of administration, mode of
application (e.g., cell sheet or cell suspension), cell engraftment
site, target diseases, and suitability of the test systems, among
other parameters. If necessary, conduct studies on a suitable
animal model. If there is a possibility of tumorigenicity or ma-
lignant transformation, provide justiﬁcation for the use of the
product in question, taking into consideration the anticipated
efﬁcacy. (Note: For tumorigenicity studies, it is very important to
accurately assess tumorigenicity of the ﬁnal product that will be
used in patients. However, tumorigenicity may have to be
evaluated using cells from the intermediate product if, for
various reasons, such as an insufﬁcient cell number, the cells in
the ﬁnal product cannot be used. Furthermore, when con-
ducting tumorigenicity tests in animal models, variables such as
cell dispersion, cell adhesion to scaffolding, cell density, and the
administration site may not be the same as those of the ﬁnal
product. The species, strain, and immunological state of the
animal may also affect its sensitivity. The tumorigenicity of the
ﬁnal product should be evaluated in a comprehensive manner
taking these factors into account.) The risks to the patient
arising from tumorigenicity of the ﬁnal product should be
evaluated by weighing the risks of treatment against the ben-
eﬁts of treating the disease.
7. If an exogenous gene is introduced into certain cells during the
manufacturing process, conduct tests in accordance with “Gene
Therapy Pharmaceutical Guidelines.” In particular, if viral vec-
tors are used, conduct quantitative tests to determine whether
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justiﬁcation for the test employed. Describe the safety of the
transgene and its products on the basis of their characteristics.
For cells, discuss the possibility of changes in cell growth and of
tumor formation, including benign tumors and malignant
transformation. When using a vector that can get inserted into
a chromosome, consider the necessity of evaluating abnormal
proliferative characteristics and/or tumorigenicity and imple-
menting long-term follow-up.
8. Consider conducting rationally designed general toxicological
tests if the product, including an animal-derived product, is easy
to obtain and if doing so will produce useful information
regarding its clinical application. When conducting general
toxicology tests, refer to “Guidelines for Toxicology Studies on
Pharmaceuticals,” which is an appendix in the document enti-
tled “Guidelines on Toxicology Studies Required for Regulatory
Approval for the Manufacture or Import of Pharmaceuticals”
(Drug Evaluation Notiﬁcation 1:24, issued September 11, 1988,
New Drug Division /Evaluation and Licensing Division, Pharm-
ceutical Affairs Bureau, Japanese Ministry of Health and
Welfare).7. Chapter V. Studies supporting the potency or efﬁcacy of
autologous human somatic stem cell-based products
1. A well-designed study with experimental animals and/or cells
should be performed to demonstrate, to a scientiﬁcally
reasonable and technically possible extent, the functional
expression, the sustainability of effects, and/or anticipated
clinical efﬁcacy (proof of concept) of an autologous human so-
matic stem cell-based product.
2. For transgenic cells, demonstrate the expression efﬁciency,
sustainability of expression, and biological activity of the
desired products derived from the transgene. Discuss the
rationale of the transgene expression products as active in-
gredients for anticipated clinical efﬁcacy (proof of concept) of
the autologous human somatic stem cell-based product in
question.
3. Where appropriate products derived from the processing of
animal somatic stem cells and/or disease model animals are
available, use them to study the potential therapeutic efﬁcacy of
the product.
4. At the beginning of the clinical trial, detailed experimental
studies will not necessarily be required if scientiﬁc literature
and/or other information supports the prediction that the po-
tency or efﬁcacy of the product in question will be markedly
superior to that of a different therapeutic method.8. Chapter VI. Pharmacokinetics of autologous human
somatic stem cell-based products
1. Pharmacokinetic studies of the internal behavior of transgene
expression products or cells/tissues that constitute the ﬁnal
products (these studies may include assessment of the absorp-
tion and distribution in experimental animals), should be per-
formed to an extent that is technically possible and scientiﬁcally
valid. Thereby, these experiments are expected to estimate the
survival of cells/tissues administered to patients and the dura-
tion of their effects, and to determine if the intended efﬁcacy is
successfully achieved. (Note: Testing methods may include his-
tological studies, human Alu sequences ampliﬁcation by poly-
merase chain reaction (Alu-PCR), magnetic resonance imaging(MRI), positron emission tomography (PET), single photon
emission computed tomography (SPECT), and bioimaging.)
2. For autologous human somatic stem cell-based products, clarify,
in animal studies, the rationale for the administration method.
In particular, extrapolate from animal experiments the systemic
distribution of the cells after systemic administration and
discuss the distribution from the point of view of clinical use-
fulness. (Note: Although it is unclear exactly where the cells
adhere with each administration route, local administration is
presumed to be preferable to systemic administration. However,
if the beneﬁts to patients can be explained, it is acceptable to use
systemic administration. In any case, an administration method
that minimizes the distribution of a somatic stem cell-based
product to organs other than the target organ would be a
rational choice. Even if the cells do localize to a site other than
the intended transplantation site, this administration method
may be used if no adverse effects on patients result. Arrhythmia
caused by osteogenesis of mesenchymal stem cells that ectopi-
cally localize to the heart is an example of an adverse effect that
can result from ectopic differentiation.)
3. When the cells or tissues are directly applied or targeted to a
speciﬁc site (e.g., tissue) where they are expected to act, clarify
the localization, and discuss the effect of the localization on the
efﬁcacy and safety of the product.9. Chapter VII. Preliminary analysis of clinical trials
The main purpose of the present guideline is to outline points to
consider for evaluating the quality and safety of autologous human
somatic stem cell-based products, either at the time of application
formarketing authorization or at the beginning of an investigational
clinical trial. In the latter case, it is necessary to determine, while
taking into consideration the clinical usefulness, whether there are
any quality and/or safety problems that might impede the initiation
of human clinical trials. Thus, quality and nonclinical-safety as-
sessments for the decision to initiate the investigational clinical
trials of the product in question should be considered in reference to
the points outlined below. Any presumed risk factors associated
with product quality and safety should be eliminated, as much as
possible, using up-to-date scientiﬁc and technologicalmethods, and
the scientiﬁc appropriateness should be clearly described. Any
remaining risks should beweighed against the risks associatedwith
not performing the trials on patients that suffer from diseases that
are serious and life-threatening, that involve marked functional
impairment or a marked decrease in quality of life (QOL) resulting
from the loss of physical function or form, or for which existing
therapies have limitations and do not result in a cure. Furthermore,
it is necessary to entrust the patient with the right to make a deci-
sion after receiving all of the available information, including all
information on identiﬁed/presumed risks and anticipated beneﬁts.
1. Target disease.
2. Target subjects and patients who should be excluded as
participants
3. Details of the therapy to be performed in the subjects, including
the application of autologous human somatic stem cell-based
products and drugs used concomitantly. (Note: If it is antici-
pated that drugs will be coadministered in order to maintain,
enhance, and/or induce the function of administered or trans-
planted cells, verify the intended activity of the drugs either
in vitro or in vivo.)
4. The rationale for conducting the clinical trials in light of existing
therapeutic methods.
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currently known risks and beneﬁts of the product.
Clinical trials should have an appropriate study design and
clearly speciﬁed endpoints. They should be designed depending
on the desired cells/tissues, target disease, and method of
application.
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